CG Oncology (CGON) Return on Capital Employed (2024 - 2026)

CG Oncology has reported Return on Capital Employed for 3 years, with the latest figure at 23.16% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 446.0% year-over-year to 23.16%; the trailing twelve-month figure through Mar 2026 stood at 23.16% (down 446.0% YoY), and the FY2025 full-year result was 25.7%, down 53.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 23.16%, up from 26.14% in the prior quarter.
• The five-year high for Return on Capital Employed was 14.6% in Q2 2024, with the low at 26.29% in Q3 2025.
• Historically, Return on Capital Employed has averaged 20.63% across 3 years, with a median of 18.7% in 2025.
• The largest YoY upside for Return on Capital Employed was 71 bps in 2025 against a maximum downside of 861 bps in 2025.
• CG Oncology's Return on Capital Employed stood at 18.14% in 2024, then sank by 44 bps to 26.14% in 2025, then advanced by 11 bps to 23.16% in 2026.
• The last three Return on Capital Employed figures came in at 23.16% (Q1 2026), 26.14% (Q4 2025), and 26.29% (Q3 2025), per Business Quant data.